Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China · Delayed Price · Currency is CNY 245.71
+4.94 (2.05%)
At close: Oct 30, 2026
SHA:688506 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 100,770 | 133,400 | 76,884 | 56,100 | - | - | |
Market Cap Growth | -28.99% | 73.51% | 37.05% | - | - | - |
Enterprise Value | 100,924 | 131,013 | 73,458 | 56,019 | - | - |
Last Close Price | 244.07 | 323.10 | 191.73 | 139.90 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 20.74 | - | - | - |
Forward PE | - | 88.17 | 71.91 | - | - | - |
PS Ratio | 39.55 | 52.93 | 13.20 | 99.85 | - | - |
PB Ratio | 18.44 | 20.14 | 19.79 | 369.39 | - | - |
P/TBV Ratio | 18.60 | 20.24 | 19.92 | 452.87 | - | - |
P/FCF Ratio | - | - | 19.34 | - | - | - |
P/OCF Ratio | - | - | 18.94 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 39.61 | 51.99 | 12.62 | 99.70 | - | - |
EV/EBITDA Ratio | - | - | 19.57 | - | - | - |
EV/EBIT Ratio | - | - | 19.93 | - | - | - |
EV/FCF Ratio | - | - | 18.48 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.21 | 0.56 | 0.53 | 4.53 | 0.59 | 0.87 |
Debt / EBITDA Ratio | - | - | 0.55 | - | - | - |
Debt / FCF Ratio | - | - | 0.52 | - | - | - |
Net Debt / Equity Ratio | 0.03 | -0.92 | -0.95 | 1.87 | -0.49 | 0.40 |
Net Debt / EBITDA Ratio | -0.15 | 8.51 | -0.98 | -0.39 | 1.68 | -1.21 |
Net Debt / FCF Ratio | -0.08 | 5.77 | -0.93 | -0.41 | 1.56 | -0.74 |
Asset Turnover | 0.20 | 0.27 | 1.36 | 0.33 | 0.48 | 0.80 |
Inventory Turnover | 1.59 | 1.68 | 1.87 | 2.00 | 2.59 | 2.75 |
Quick Ratio | 3.49 | 5.14 | 2.99 | 0.52 | 1.73 | 0.62 |
Current Ratio | 4.92 | 5.41 | 3.19 | 0.74 | 1.94 | 0.90 |
Return on Equity (ROE) | -20.01% | -20.05% | 183.64% | -143.77% | -44.62% | -25.51% |
Return on Assets (ROA) | -5.35% | -5.38% | 53.82% | -28.74% | -14.01% | -10.00% |
Return on Invested Capital (ROIC) | -33.83% | - | - | -172.17% | -70.10% | -38.81% |
Return on Capital Employed (ROCE) | -10.00% | -8.40% | 71.50% | -211.60% | -26.30% | -33.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -1.25% | -0.79% | 4.82% | -1.39% | - | - |
FCF Yield | -1.97% | -0.80% | 5.17% | -1.24% | - | - |
Payout Ratio | - | - | 1.03% | - | - | - |
Buyback Yield / Dilution | -2.41% | -0.72% | -0.14% | -10.56% | -1.38% | -3.64% |
Total Shareholder Return | -2.41% | -0.72% | -0.14% | -10.56% | -1.38% | -3.64% |